Monitoring and Feedback in Substance Abuse Treatment

Phase 1

Completed

• Conditions: Substance Abuse
• Interventions: Behavioral: Monitoring and Feedback Intervention

• Registration Number: NCT01465490
• Lead Sponsor: Treatment Research Institute

Brief Summary

This is a three-staged study to develop and evaluate a monitoring instrument and associated intervention, as follows:

Stage 1 - Develop and determine the reliability, validity, and sensitivity to change of a brief Multidimensional Monitoring Instrument (MMI) for clients in outpatient substance abuse treatment (SAT).

Stage 2 - Develop a Monitoring and Feedback Intervention (MFI) that uses the MMI. As part of this process, create a manual, training materials, and competence and adherence measures, and conduct a feasibility study within an outpatient SAT unit to refine the intervention and associated materials and measures.

Stage 3 - Conduct a randomized clinical trial (RCT) to determine the preliminary efficacy of the MFI compared to treatment as usual (TAU) for clients in outpatient SAT. In this pilot study, it is hypothesized that the MFI will positively impact the treatment process, and short-term, during treatment, outcomes.

Detailed Description

In Stage 1, 20 substance abuse treatment (SAT) professionals, including clinicians, supervisors, and administrators, will participate in clinical focus groups. Clinical focus group members will review and discuss the MMI, its potential uses, and specific strategies around its implementation. Also in Stage 1, 240 clients will participate in a formal psychometric evaluation study of the Multidimensional Monitoring Instrument (MMI). These participants will complete a study intake meeting, which will include providing locator information (to facilitate scheduling research appointments), a baseline ASI6, and the MMI. After this intake, participants will complete 5 additional MMIs during a 4-week period. At the one and two-month follow-up research meetings, participants will complete the ASI6 and provide specimens for urine drug screens (UDSs). To ensure adequate resource management, participants who leave treatment at the program will not be continued in the study. Participants who are incarcerated during the study will not be contacted while in custody.

In Stage 2, the Monitoring and Feedback Intervention (MFI), the MFI Manual, and associated training materials will be completed with expert consultation. Also in Stage 2, 35 clients will participate in the MFI Feasibility Study. They will complete a baseline ASI6, as well as brief research assessments at 1-month post study intake and 2 months later (i.e., at the conclusion of their participation). Client participants will also provide specimens for UDSs. Clients will complete the MMI with their counselors on a regular basis, about weekly. Five randomly selected counselors will also participate in the Feasibility Study. They will meet with research staff for training and to periodically complete questionnaires/interviews. All individual counseling sessions will be recorded using a digital voice recorder.

During Stage 3, 112 clients will participate in a randomized clinical trial (RCT) of the intervention (MFI). These participants will complete a baseline ASI6, as well as brief research assessments at 1-month post study intake and 2 months later (i.e., at the conclusion of their participation). They will also provide samples for UDSs. Clients will be randomized so that one-half will receive treatment as usual (TAU; with the exception that counseling sessions will be digitally recorded), and one-half will receive MFI. Clients in the MFI group will participate in standard treatment and complete the MMI weekly with their counselors at the beginning of each individual counseling session. Also, a total of 8 counselors will be randomly selected to participate. They will be randomized so that 4 will provide TAU, and 4 will provide MFI. All counselors will meet with research staff for training and to periodically complete questionnaires/interviews. All individual counseling sessions will be recorded using a digital voice recorder.

Study Timeline

• Study Start: 2007-09
• Primary Completion: 2011-08
• Study Completion: 2011-08
• Study First Submitted: 2011-11-01
• Study First Submitted QC: 2011-11-01
• Study First Posted: 2011-11-04
• Status Verified: 2023-11
• Last Update Submitted: 2023-11-16
• Last Update Posted: 2023-11-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 327

Inclusion Criteria

• Client receiving intensive outpatient treatment at participating program
• Counselor employed by participating program

Exclusion Criteria

• Client unable to speak English
• Client too cognitively impaired to give informed consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Monitoring and Feedback Intervention	Monitoring and Feedback Intervention	-

Primary Outcome Measures

Name	Time	Method
Treatment attendance	3 months after consent	Client participant's treatment attendance is obtained from treatment program clinical record.

Secondary Outcome Measures

Name	Time	Method
Discharge status	3 months after consent	Client participant's discharge status is obtained from treatment program clinical record.
Discharge date	3 months after consent	Client participant's discharge date is obtained from treatment program clinical record.
Urine screen results	3 months after consent	Client participant's urine screen results are obtained from treatment program clinical record.

Trial Locations

Locations (4)

Presbyterian Medical Center; 🇺🇸 Philadelphia, Pennsylvania, United States

Rehab After Work; 🇺🇸 Philadelphia, Pennsylvania, United States

Jefferson Intensive Outpatient; 🇺🇸 Philadelphia, Pennsylvania, United States

Sobriety Through Outpatient; 🇺🇸 Philadelphia, Pennsylvania, United States